115 related articles for article (PubMed ID: 28952225)
1. VHL-TGFBI signaling is involved in the synergy between 5-aza-2'-deoxycytidine and paclitaxel against human renal cell carcinoma.
Shang D; Xian S; Han T; Li X; Liu Y
J BUON; 2017; 22(4):1038-1045. PubMed ID: 28952225
[TBL] [Abstract][Full Text] [Related]
2. VHL-TGFBI signaling is involved in the synergy between 5-aza-2'-deoxycytidine and paclitaxel against human renal cell carcinoma.
Shang D; Xian S; Han T; Li X; Liu Y
J BUON; 2017; 22(2):500-507. PubMed ID: 28534376
[TBL] [Abstract][Full Text] [Related]
3. 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-β-catenin expression.
Shang D; Liu Y; Xu X; Han T; Tian Y
Cancer Lett; 2011 Dec; 311(2):230-6. PubMed ID: 21880414
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of the synergy of 5-aza-2'-deoxycytidine and paclitaxel against renal cell carcinoma.
Han T; Shang D; Xu X; Tian Y
World J Surg Oncol; 2012 Sep; 10():183. PubMed ID: 22950635
[TBL] [Abstract][Full Text] [Related]
5. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.
Shang D; Liu Y; Yang P; Chen Y; Tian Y
Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602
[TBL] [Abstract][Full Text] [Related]
6. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel.
Shang D; Ito N; Kamoto T; Ogawa O
Urology; 2007 May; 69(5):1007-12. PubMed ID: 17482960
[TBL] [Abstract][Full Text] [Related]
7. Protein tyrosine phosphatase ζ enhances proliferation by increasing β-catenin nuclear expression in VHL-inactive human renal cell carcinoma cells.
Shang D; Xu X; Wang D; Li Y; Liu Y
World J Urol; 2013 Dec; 31(6):1547-54. PubMed ID: 23588815
[TBL] [Abstract][Full Text] [Related]
8. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
9. von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR.
Danilin S; Sourbier C; Thomas L; Rothhut S; Lindner V; Helwig JJ; Jacqmin D; Lang H; Massfelder T
Carcinogenesis; 2009 Mar; 30(3):387-96. PubMed ID: 19056930
[TBL] [Abstract][Full Text] [Related]
10. Synergistic inhibitory effects of 5-aza-2'-deoxycytidine and cisplatin on urothelial carcinoma growth via suppression of TGFBI-MAPK signaling pathways.
Shang D; Li G; Zhang C; Liu Y
Biochem Cell Biol; 2022 Apr; 100(2):115-124. PubMed ID: 34890285
[TBL] [Abstract][Full Text] [Related]
11. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells.
Peruzzi B; Athauda G; Bottaro DP
Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14531-6. PubMed ID: 16983094
[TBL] [Abstract][Full Text] [Related]
12. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
[TBL] [Abstract][Full Text] [Related]
13. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
Yuen JS; Akkaya E; Wang Y; Takiguchi M; Peak S; Sullivan M; Protheroe AS; Macaulay VM
Mol Cancer Ther; 2009 Jun; 8(6):1448-59. PubMed ID: 19509240
[TBL] [Abstract][Full Text] [Related]
14. Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors.
Ivanov SV; Ivanova AV; Salnikow K; Timofeeva O; Subramaniam M; Lerman MI
Biochem Biophys Res Commun; 2008 Jun; 370(4):536-40. PubMed ID: 18359287
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
[TBL] [Abstract][Full Text] [Related]
16. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
17. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of nuclear factor kappa B in renal cell carcinoma.
Morais C; Gobe G; Johnson DW; Healy H
Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
[TBL] [Abstract][Full Text] [Related]
20. Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma.
Craven RA; Hanrahan S; Totty N; Harnden P; Stanley AJ; Maher ER; Harris AL; Trimble WS; Selby PJ; Banks RE
Proteomics; 2006 Jul; 6(13):3880-93. PubMed ID: 16739133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
